163 related articles for article (PubMed ID: 38349333)
1. The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy.
Gay CL; Hanley PJ; Falcinelli SD; Kuruc JD; Pedersen SM; Kirchherr J; Raines SLM; Motta CM; Lazarski C; Chansky P; Tanna J; Shibli A; Datar A; McCann CD; Sili U; Ke R; Eron JJ; Archin N; Goonetilleke N; Bollard CM; Margolis DM
J Infect Dis; 2024 Mar; 229(3):743-752. PubMed ID: 38349333
[TBL] [Abstract][Full Text] [Related]
2. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
[TBL] [Abstract][Full Text] [Related]
3. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.
Archin NM; Kirchherr JL; Sung JA; Clutton G; Sholtis K; Xu Y; Allard B; Stuelke E; Kashuba AD; Kuruc JD; Eron J; Gay CL; Goonetilleke N; Margolis DM
J Clin Invest; 2017 Aug; 127(8):3126-3135. PubMed ID: 28714868
[TBL] [Abstract][Full Text] [Related]
4. HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.
Sung JA; Patel S; Clohosey ML; Roesch L; Tripic T; Kuruc JD; Archin N; Hanley PJ; Cruz CR; Goonetilleke N; Eron JJ; Rooney CM; Gay CL; Bollard CM; Margolis DM
Mol Ther; 2018 Oct; 26(10):2496-2506. PubMed ID: 30249388
[TBL] [Abstract][Full Text] [Related]
5. Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection.
Gay CL; Kuruc JD; Falcinelli SD; Warren JA; Reifeis SA; Kirchherr JL; James KS; Dewey MG; Helms A; Allard B; Stuelke E; Gamble A; Plachco A; Gorelick RJ; Eron JJ; Hudgens M; Garrido C; Goonetilleke N; DeBenedette MA; Tcherepanova IY; Nicolette CA; Archin NM; Margolis DM
Sci Rep; 2020 Mar; 10(1):5134. PubMed ID: 32198428
[TBL] [Abstract][Full Text] [Related]
6. Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.
Scully EP; Aga E; Tsibris A; Archin N; Starr K; Ma Q; Morse GD; Squires KE; Howell BJ; Wu G; Hosey L; Sieg SF; Ehui L; Giguel F; Coxen K; Dobrowolski C; Gandhi M; Deeks S; Chomont N; Connick E; Godfrey C; Karn J; Kuritzkes DR; Bosch RJ; Gandhi RT
Clin Infect Dis; 2022 Oct; 75(8):1389-1396. PubMed ID: 35176755
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal
Garrido C; Abad-Fernandez M; Tuyishime M; Pollara JJ; Ferrari G; Soriano-Sarabia N; Margolis DM
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593039
[TBL] [Abstract][Full Text] [Related]
8. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Archin NM; Liberty AL; Kashuba AD; Choudhary SK; Kuruc JD; Crooks AM; Parker DC; Anderson EM; Kearney MF; Strain MC; Richman DD; Hudgens MG; Bosch RJ; Coffin JM; Eron JJ; Hazuda DJ; Margolis DM
Nature; 2012 Jul; 487(7408):482-5. PubMed ID: 22837004
[TBL] [Abstract][Full Text] [Related]
9. Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.
Gay CL; James KS; Tuyishime M; Falcinelli SD; Joseph SB; Moeser MJ; Allard B; Kirchherr JL; Clohosey M; Raines SLM; Montefiori DC; Shen X; Gorelick RJ; Gama L; McDermott AB; Koup RA; Mascola JR; Floris-Moore M; Kuruc JD; Ferrari G; Eron JJ; Archin NM; Margolis DM
J Infect Dis; 2022 Mar; 225(5):856-861. PubMed ID: 34562096
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.
Archin NM; Bateson R; Tripathy MK; Crooks AM; Yang KH; Dahl NP; Kearney MF; Anderson EM; Coffin JM; Strain MC; Richman DD; Robertson KR; Kashuba AD; Bosch RJ; Hazuda DJ; Kuruc JD; Eron JJ; Margolis DM
J Infect Dis; 2014 Sep; 210(5):728-35. PubMed ID: 24620025
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
Wei DG; Chiang V; Fyne E; Balakrishnan M; Barnes T; Graupe M; Hesselgesser J; Irrinki A; Murry JP; Stepan G; Stray KM; Tsai A; Yu H; Spindler J; Kearney M; Spina CA; McMahon D; Lalezari J; Sloan D; Mellors J; Geleziunas R; Cihlar T
PLoS Pathog; 2014 Apr; 10(4):e1004071. PubMed ID: 24722454
[TBL] [Abstract][Full Text] [Related]
12. Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir.
Sung JA; Lam S; Garrido C; Archin N; Rooney CM; Bollard CM; Margolis DM
J Infect Dis; 2015 Jul; 212(2):258-63. PubMed ID: 25589335
[TBL] [Abstract][Full Text] [Related]
13. Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells.
Sung JA; Sholtis K; Kirchherr J; Kuruc JD; Gay CL; Nordstrom JL; Bollard CM; Archin NM; Margolis DM
EBioMedicine; 2017 Sep; 23():52-58. PubMed ID: 28803740
[TBL] [Abstract][Full Text] [Related]
14. Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency.
Zerbato JM; Khoury G; Zhao W; Gartner MJ; Pascoe RD; Rhodes A; Dantanarayana A; Gooey M; Anderson J; Bacchetti P; Deeks SG; McMahon J; Roche M; Rasmussen TA; Purcell DF; Lewin SR
EBioMedicine; 2021 Mar; 65():103241. PubMed ID: 33647768
[TBL] [Abstract][Full Text] [Related]
15. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC
J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment.
White CH; Beliakova-Bethell N; Lada SM; Breen MS; Hurst TP; Spina CA; Richman DD; Frater J; Magiorkinis G; Woelk CH
Front Immunol; 2018; 9():603. PubMed ID: 29706951
[TBL] [Abstract][Full Text] [Related]
17. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
[TBL] [Abstract][Full Text] [Related]
18. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
[TBL] [Abstract][Full Text] [Related]
19. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
[TBL] [Abstract][Full Text] [Related]
20. Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8
Mota TM; McCann CD; Danesh A; Huang SH; Magat DB; Ren Y; Leyre L; Bui TD; Rohwetter TM; Kovacs CM; Benko E; MacLaren L; Wimpelberg A; Cannon CM; Hardy WD; Safrit JT; Jones RB
J Virol; 2020 Apr; 94(9):. PubMed ID: 32051267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]